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E-mail address: k.tanaka@idac.tohoku.ac.jp (K. TanWe investigated the fate of budding yeast treated with nocodazole, a microtubule-depolymerizing
drug. Cells died after mitotic arrest while staying in mitosis, suggesting that mitotic cell death,
but not mitotic slippage, mainly occurs in nocodazole-treated cells. Nocodazole-treated cells
showed features of apoptotic-like cell death, but not those of cell lysis or autophagy. Consistently,
mitochondria-dependent production of reactive oxygen species was involved in the cell death. Sim-
ilar cell death was also seen in cells after mitotic arrest by perturbation of the anaphase-promoting
complex/cyclosome. In addition, caspase activity was found in nocodazole-treated cells, which was
independent of the metacaspase, Mca1. Our results suggest that budding yeast can be a model to
study mitotic cell death in cancer treatment with antimitotic drugs.
 2010 Federation of European Biochemical Societies. Published by Elsevier B.V. All rights reserved.1. Introduction
Antimitotic drugs like vinca alkaloids and paclitaxel are widely
used for cancer therapy [1]. Inhibitors of Eg5, a kinesin-5 motor,
are now being tested as new antimitotic drugs that do not affect
microtubule dynamics and thus may reduce side effects like neu-
ropathy [2]. These drugs prevent proper kinetochore-microtubule
interaction and thus activate spindle assembly checkpoint (SAC)
[3]. The effect of short exposure to these drugs is reversible, but
sustained mitotic arrest leads to cell death, mainly by two path-
ways [4–6]. One is ‘mitotic cell death’, which means cells die while
they stay in mitosis. This is assumed to be a form of apoptosis in
which caspases are involved in most cases. Another mechanism
is cell death after escaping from mitotic arrest and entering into
next G1, known as ‘mitotic slippage’ or ‘adaptation’. Gradual degra-
dation of cyclin B1 is considered to be responsible for mitotic slip-
page [7]. In some cases, cells continue dividing, leading to
resistance to chemotherapy, or senescence (i.e. cells stop dividing)
following mitotic slippage. Prediction of the cell response to anti-
mitotic drugs has clinical importance, although little is knownchemical Societies. Published by E
C, anaphase-promoting com-
I, propidium iodide; TUNEL,
TP nick-end-labeling; GFP,
aka).about the mechanisms leading to cell death following treatment
with antimitotic drugs [8,9].
The mechanism of SAC is well conserved between yeast and hu-
man cells [3,5]. Apoptosis has long been thought to be speciﬁc in
multicellular organisms, but it has been revealed that yeast shows
apoptotic-like cell death in a number of situations [10]. When
yeast cells die with various kinds of stresses or aging, markers
characteristic for apoptosis become positive, such as DNA fragmen-
tation and phosphatidyl serine externalization. Like apoptosis in
animal cells, reactive oxygen species (ROS) play an important role
in yeast apoptosis. In addition, there are yeast proteins homolo-
gous to apoptosis regulators in animal cells such as caspases, and
they are reported to be indeed involved in yeast apoptosis [10].
Thus budding yeast may prove a useful model organism for the
study of cell death caused by antimitotic drugs. Here we addressed
the mechanism for such cell death in yeast.
2. Materials and methods
2.1. Yeast cell culture
Saccharomyces cerevisiae strains used in this study were in the
W303 or S288C background. Yeast cells were grown in standard
YPAD media or selective synthetic complete media. To synchronize
cells in G1 phase, a-factor was added as described previously [11].
Nocodazole were added to 15 lg/mL and readded after 5 h.lsevier B.V. All rights reserved.
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Fig. 1. Nocodazole induces cell death in budding yeast. (A) A ﬂow cytometry
analysis of budding yeast treated with nocodazole. Cells were released from a-
factor arrest, and treated with either DMSO or nocodazole. Samples were taken
every 2 h and subjected to a ﬂow cytometry analysis. (B) Detection of dead cells.
Cells treated with either DMSO or nocodazole for 10 h after release from a-factor
arrest were stained with methylene-blue. Scale bar, 10 lm. (C) Increase of dead
cells during nocodazole treatment. Percentage of dead cells judged by methylene-
blue staining was plotted according to the time after release from a-factor arrest.
Cells were treated with DMSO (d), nocodazole (N), or nocodazole + cycloheximide
(added to 60 lg/mL after 2 h from nocodazole treatment, ). Values are the mean of
2388 K. Endo et al. / FEBS Letters 584 (2010) 2387–23922.2. Flow cytometry
For ﬂow cytometry analysis, yeast cells were ﬁxed in 70% etha-
nol for 2 h on ice. Cells were collected by centrifugation, resus-
pended in RNase A solution (0.2 mg/mL in 50 mM Tris pH7.8),
and incubated for 6 h at 37 C. Samples were then stained with
0.1 mg/mL propidium iodide (PI) and sonicated brieﬂy before mea-
sured with Cytomics FC500 (Beckman Coulter).
2.3. Detection of yeast cell death and apoptotic markers
To visualize dead cells, the culture was incubated with 20 mg/
mL methylene-blue (Sigma) for 5 min at room temperature. For
survival plating, 200 cells were plated on YPAD plates, and the
number of surviving colonies were determined after 2 days incuba-
tion at 25 C. For the terminal deoxynucleotidyl transferase-medi-
ated dUTP nick-end-labeling (TUNEL) assay, cells were prepared as
described previously [12] and labeled using the DeadEnd Fluoro-
metric TUNEL System (Promega) and observed under a ﬂuores-
cence microscope. For the Annexin V staining, samples were
prepared as described previously [12] and stained using ApoAlert
Annexin V Apoptosis Kit (Clontech Laboratories) before observa-
tion under a ﬂuorescence microscope.
2.4. Western blotting
Equivalent amount of cells were directly lysed with 2  LDS
sample buffer (Invitrogen), boiled for 5 min, and then subjected
to SDS–PAGE followed by immunoblotting with anti-HA antibody
(3E10; 1:1000), anti-myc antibody (9E10; 1:1000), anti-Cdc28
antibody (1:1000; Santa Cruz), or anti-green ﬂuorescent protein
(GFP) antibody (1:1000; Roche) for 1 h at room temperature. Sec-
ondary antibody was goat anti-mouse or rabbit IgG conjugated to
horse radish peroxidase (1:4000; Santa Cruz) and detected by a
chemiluminescnce system (GE Healthcare Bioscience).
2.5. Detection of reactive oxygen species (ROS)
Yeast cells were washed twice with distilled water before incu-
bation with 10 lM of H2DCF-DA (Molecular Probes) in distilled
water for 40 min at 30 C. PI was also added at 5 ng/mL to discrim-
inate dead cells. Samples were washed three times with distilled
water and observed under a ﬂuorescence microscope.
2.6. Detection of caspase activity
Yeast cells were washed twice with distilled water before incu-
bation with D2R reagent (CaspSCREEN Flow Cytometric Apoptosis
Detection Kit; BioVision) for 40 min at 30 C. After washing cells
once with distilled water, PI was added at 5 ng/mL, and samples
were incubated for 5 min at room temperature. Samples were
washed twice with distilled water and observed under a ﬂuores-
cence microscope.triplicate measurements, counting more than 100 cells each time. Error bars
represent standard deviations. (D) Survival of nocodazole-treated cells. Survival
was measured by colony-forming cells on YPAD plates, and 100% corresponds to the
number of colonies at time zero. Error bars represent standard deviations.3. Results and discussion
3.1. Cell death of budding yeast after prolonged treatment with
nocodazole
To investigate the outcome of a prolonged mitotic arrest in bud-
ding yeast, we treated yeast cells with a microtubule-depolymeriz-
ing drug, nocodazole after release from a-factor treatment. In 2 h,
most of the yeast cells arrested in mitosis with large bud and 2C
DNA content as judged by a ﬂow cytometry (Fig. 1A), which is a re-
sult of SAC activation. In 4 h, the peak of DNA content at 2Cdecreased and shifted to right due to increase in mitochondrial
DNA (Fig. 1A) [13]. When cells were treated with nocodazole for
a longer period (>6 h), 2C peak decreased further and cells showed
broad range of DNA contents, including less than 1C (Fig. 1A),
which may be due to the presence of dead cells. We therefore
checked possible appearance of dead cells with methylene-blue,
which stains dead cells with defective cell wall integrity. As a
K. Endo et al. / FEBS Letters 584 (2010) 2387–2392 2389control, the DMSO-treated cells were used and their majority ex-
cluded methylene-blue as expected (Fig. 1B). By contrast, a fraction
of nocodazole-treated cells were stained with the dye (Fig. 1B).
Nearly 40% of cells were dead after nocodazole treatment for
10 h (Fig. 1C). We also judged cell death by colony formation on
YPAD plates after nocodazole treatment. The percentage of cells
losing ability to form colonies similarly increased during the time
course as the percentage of cells stained with methylene-blue
(Fig. 1D), but the former was constantly higher than the latter, sug-
gesting that there were a fraction of cells losing ability for colony
formation but maintaining cell wall integrity. When cells were
treated with cycloheximide to inhibit protein synthesis after mito-
tic arrest by nocodazole, cell death was signiﬁcantly suppressed
(Fig. 1C). These data suggest that yeast cell death after prolonged
nocodazole treatment is an active process requiring protein
synthesis.
3.2. Mitotic cell death occurs in nocodazole-treated cells
Human cells treated with antimitotic drugs arrest at mitosis
and then either slip out to the next cell cycle (mitotic slippage)0 2 4 6 8 10
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Fig. 2. Mitotic cell death occurs in nocodazole-treated cells. (A) Expression of Sic1
or Clb2 during nocodazole treatment. Cells containing Sic1-3HA or Clb2-12myc
were released from a-factor arrest, and treated with nocodazole. Samples were
taken every 2 h and subjected to a western blotting with anti-HA or anti-myc
antibody. Cdc28 expression was shown as a control. (B) Percentage of cells showing
Sic1 or Clb2 signal during nocodazole treatment. Cells containing Sic1- or Clb2-GFP
were released from a-factor arrest, and treated with nocodazole. Samples were
taken every 2 h, stained with PI, and observed under a ﬂuorescence microscope. (C)
Increase of dead cells in apc mutants at restrictive temperature. Percentage of dead
cells judged by methylene-blue staining was plotted according to the time at 37 C
after release from a-factor arrest. (d) Wild type cells treated with nocodazole, (N)
cdc27-1 cells, () cdc26D cells. Values are the mean of triplicate measurements,
counting more than 100 cells each time. Error bars represent standard deviations.or die while staying in mitosis (mitotic cell death) [4–6]. We ad-
dressed whether nocodazole-treated yeast cells stay in mitosis or
escape from mitotic arrest when they die, to discriminate mitotic
cell death from mitotic slippage. We ﬁrst checked the expression
of Sic1, a CDK inhibitor expressed in G1 phase, and Clb2, a yeast
Cyclin B expressed in mitosis [14], in nocodazole-treated cells
using a western blotting. Sic1 expression was clearly detected in
G1 cells, subsequently disappeared after nocodazole treatment
and became barely detectable after 10 h from the nocodazole treat-
ment (Fig. 2A). On the other hand, Clb2 appeared after cells enteredFig. 3. Apoptotic-like features in nocodazole-treated cells. (A) Nuclear morphology
of nocodazole-treated cells or apc mutants at restrictive temperature. Wild type
cells treated with DMSO (upper left) or nocodazole (upper right) for 10 h, or cdc27-1
(lower left) or cdc26D (lower right) cells cultured at 37 C for 10 h were stained
with DAPI. Note that punctate signals at cell periphery represent mitochondria [13].
Scale bar, 10 lm. (B) The TUNEL assay. Wild type cells were treated with DMSO
(upper panels) or nocodazole (lower panels) for 8 h, and TUNEL signal was detected
(right panels). DIC images were shown as reference (left panels). Scale bar, 10 lm.
(C) The Annexin V staining. Wild type cells were treated with DMSO (upper panels)
or nocodazole (lower panels) for 6 h, and Annexin V signal (middle panels) or PI
staining (right panels) was observed. DIC images were shown as reference (left
panels). Scale bar, 5 lm.
2390 K. Endo et al. / FEBS Letters 584 (2010) 2387–2392mitosis, and was detected thereafter during the time course
(Fig. 2A), suggesting that cells stayed in mitosis. Then we observed
the expression of Sic1 or Clb2 in individual cells by tagging respec-
tive proteins with GFP. Sic1 signal was lost in 2 h, and did not ap-
pear in most of the cells even after 10 h from nocodazole treatment
when nearly half of the cells were dead, judged by staining with
propidium iodide (PI) (Fig. 2B). In contrast, Clb2 signal appeared
when cells entered mitosis and remained in the majority of the
cells after 10 h of nocodazole treatment, although it was lost in a
fraction of cells (Fig. 2B). Dead cells conﬁrmed by PI staining were
found in the presence and absence of Clb2 signal with similar fre-
quency, showing that loss of Clb2 signal is not linked to cell death.
These data suggest that nocodazole-treated cells mainly die
through mitotic cell death rather than mitotic slippage.
We next addressed whether cell death is commonly seen after
prolonged mitotic arrest. For this, we used mutants of anaphase-
promoting complex/cyclosome (APC/C) at restrictive temperature.
APC/C is a ubiquitin ligase which promotes cell cycle progression
from metaphase to anaphase [3]. The percentage of dead cells in
apc mutants gradually increased during the time course, in a sim-
ilar manner as nocodazole-treated wild type cells (Fig. 2C). This
suggests that the cell death found in nocodazole-treated cells is a
common feature of cells in sustained mitotic arrest.
3.3. Apoptotic features in nocodazole-induced cell death
We investigated whether nocodazole-induced cell death shows
apoptotic-like features, like mitotic cell death in animal cells ex-
posed to antimitotic drugs. First we checked the morphology of nu-
clei by DAPI staining in nocodazole-treated cells (Fig. 3A).
Compared with DMSO-treated control cells that have uniform,
round nuclei, nocodazole-treated cells showed deformed, frag-
mented nuclei that are characteristic of yeast apoptosis [12]. Such
a nuclear morphology was also seen in apc mutants at restrictive
temperature (Fig. 3A).
Next we examined DNA fragmentation in nocodazole-treated
cells using the TUNEL assay (Fig. 3B). Many cells prove positiveA
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Fig. 4. Ruling out the involvement of cell lysis and autophagy in nocodazole-treated
cells. (A) Survival in the presence of sorbitol. Wild type cells were treated with
DMSO or nocodazole for 8 h in the presence or absence of 1.2 M sorbitol. Serial 10-
fold dilutions were spotted on a YPAD plate and incubated for 3 days at 25 C. (B)
Induction of autophagy judged by generation of GFP from GFP-Atg8. Wild type cells
expressing GFP-Atg8 were treated with nocodazole. Cell lysates were taken at
indicated periods and subjected to a western blotting with anti-GFP antibody (lanes
1–4). Cells starved in SD(-N) (lane 5) medium or treated with rapamycin (0.2 lg/
mL; lane 6) for 6 h were used as positive controls.in the TUNEL assay when they were treated with nocodazole. We
also observed the exposure of phosphatidylserine on the outer leaf-
let of the plasma membrane, which is a marker of the early stage of
apoptosis, using the Annexin V staining together with PI to check
the integrity of the plasma membrane (Fig. 3C). A considerable
fraction of the nocodazole-treated cells were positive for the An-
nexin V staining. Although some cells were stained with both An-
nexin V and PI, there were cells only stained with Annexin V as
shown in Fig. 3C, showing that externalized phosphatidylserine
was stained with Annexin V in cells maintaining cell wall integrity.
Although all of these data support the idea that apoptotic-like
cell death occurs in nocodazole-treated cells, we examined the
possibility that other mechanisms are also involved in the noco-
dazole-induced cell death. One concern was that increased cell size
after nocodazole treatment could result in cell lysis, as shown in
cdc13-1 cells at restrictive temperature [15]. Therefore, we tested
the viability of nocodazole-treated cells in the presence of 1.2 M
sorbitol as an osmotic stabilizer (Fig. 4A). Sorbitol did not markedly
improve colony formation of nocodazole-treated cells, suggesting
that cell lysis was not the main cause of the nocodazole-induced
cell death.
We also checked the involvement of autophagy in the nocodaz-
ole-induced cell death. Autophagy is related to cell survival in
starved conditions, but also suggested to be a mechanism of pro-
grammed cell death [16,17]. We observed the induction of autoph-
agy using GFP-ATG8 (Fig. 4B) [18]. Atg8 is an autophagy-related
molecule and degraded in vacuoles when autophagy is induced.
When autophagy is induced in the absence of nitrogen (SD(N))
or by rapamycin treatment, GFP-ATG8 is processed to GFP, as
GFP is relatively stable compared with ATG8 (Fig. 4B). On the other
hand, processing from GFP-ATG8 to GFP was not seen in nocodaz-
ole-treated cells (Fig. 4B), suggesting that autophagy was not in-
duced in nocodazole-treated cells.
3.4. ROS production and caspase activity in nocodazole-treated cells
It was reported that production of ROS is important for the
induction of apoptosis [19]. We examined the production of ROS
in nocodazole-treated cells using H2DCF-DA, which becomes ﬂuo-
rescent by oxidization. As shown in Fig. 5A, ROS production was
seen in nocodazole-treated cells. Many of the ROS-producing cells
were dead, as judged by staining with PI, while some of them were
not stained with PI, which were probably in an early apoptotic pro-
cess. This result suggests that ROS production is involved in the
nocodazole-induced cell death.
ROS is mainly produced in mitochondria through electron
transport chain [19]. Therefore, we checked cell death in respira-
tion-defective cells. In a rho-zero strain, which are defective in
mitochondrial DNA and respiration, nocodazole-induced cell death
was suppressed (Fig. 5B). Cell death was also suppressed when a
rho-zero-version of an apc mutant was cultured at high tempera-
ture (Fig. 5C). In addition, cells lacking electron transport chain
components also showed reduced cell death after nocodazole
treatment (Fig. 5D). These data suggest that ROS produced mainly
in mitochondria is involved in cell death after mitotic arrest.
Next we checked caspase activity in nocodazole-treated cells.
To detect caspase activity, we used D2R, a substrate that becomes
ﬂuorescent by caspase activity [20]. It was reported that D2R spe-
ciﬁcally detects caspase activity, avoiding non-speciﬁc signal from
dead cells, which is the case when FITC-VAD is used [20]. As shown
in Fig. 6A, nocodazole-treated cells showed D2R signal. Many of the
cells with D2R signal were dead, as judged by staining with PI,
although some cells were only positive for D2R signal, showing
the speciﬁcity of the signal. Yeast has a metacaspase, Mca1, which
shares a homology with caspases in animal cells [21]. But caspase
activity was detected even in the absence of Mca1 (data not
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compared with wild type cells (Fig. 6B), suggesting that the cas-
pase activity found in nocodazole-treated cells is not dependent
on the metacaspase. Metacaspase-independent caspase activity
has been also reported in several other situations when apoptosisis induced in yeast [22]. ROS production was seen in mca1D cells
treated with nocodazole (Fig. 6C), further conﬁrming that Mca1
is not involved in the nocodazole-induced cell death.
In this paper, we demonstrated that yeast cells treated with
nocodazole eventually resulted in mitotic cell death with apopto-
tic-like features. Mitotic cell death may be a common fate of cells
after sustained mitotic arrest, as apc mutants (cdc26 and cdc27)
died at restrictive temperature in a similar manner to nocodaz-
ole-treated cells. Consistently, Foland et al. reported that a yeast
strain sensitive to paclitaxel due to mutations in b-tubulin showed
mitotic block and apoptotic-like cell death in the presence of pac-
litaxel [23]. Madeo et al. reported that cell division cycle mutants
cdc1, cdc19, cdc25, cdc29 (arrest at G1 phase), cdc2, cdc9, cdc46 (ar-
rest at S phase), and cdc31 (arrest at G2/M transition) did not show
markers of apoptosis [12]. Probably apoptotic pathway is not acti-
vated when cells arrest at these phases. They also mentioned that
2392 K. Endo et al. / FEBS Letters 584 (2010) 2387–2392cdc20 cells, which arrest at mitosis, showed unfragmented nuclei.
The reason for the difference in nuclear morphology of cdc20 cells
compared with cdc26 and cdc27 cells is currently unknown.
Increasing amounts of evidence suggest that yeasts have ances-
tral programmed cell death machineries, and apoptotic-like cell
death through ROS generation was seen in yeast cells treated with
numbers of antitumor drugs [24]. Our results suggest that budding
yeast can be a model to study mitotic cell death caused by antimi-
totic drugs. As nocodazole is a widely used antimitotic drug effec-
tive for wild type yeast cells in contrast to paclitaxel, it is
advantageous for further study on the cell death mechanisms.
We need to elucidate the mechanism linking mitotic arrest to
ROS production, as well as the activation mechanism of caspase-
like activity, and also need to identify proteases responsible for
the caspase-like activity. In plants, it was reported that non-cas-
pase proteases show the caspase-like activity and cause cell death
[25]. Studying the mechanism of yeast cell death by antimitotic
drugs will contribute not only to the improvement of cancer ther-
apy, but also to the advance of antifungal therapy.
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